title: Drug therapy for nocturnal enuresis. Current treatment recommendations.
abstract: It is estimated that enuresis occurs in 5 to 7 million children in the United States. The treatment approach for enuresis is controversial, in large part due to a lack of consensus as to the exact cause of enuresis. Several factors either alone or together may contribute to this syndrome. In addition, there is strong evidence of a genetic component to enuresis. Pharmacotherapy continues to be the preferred treatment for both physicians and families. The most widely used drugs include antidepressants, anticholinergics, and desmopressin. The tricyclic antidepressant imipramine has been used extensively since the 1960s. The exact mechanism of action in enuresis is unknown although it appears to be related to the anticholinergic and antispasmodic effects of the drug. The most common adverse effects reported with imipramine include personality changes, insomnia, anorexia and anxiety. There has been renewed interest in antidiuretic treatment of enuresis. Researchers have found that enuretic children do not have the ability to reduce urine volume at night or concentrate the urine they produce during the night. Clinical trials with desmopressin administered by nasal inhalation report a marked reduction in enuretic episodes. Adverse effects were limited to nasal complaints, rhinitis, or epistaxis. Additional long term studies are needed to delineate desmopressin's role in therapy. Although the number of options for treatment of enuresis is expanding, criteria to predict patient response need to be defined.
authors.affiliation: Center for the Research of Hypertension, Cardiovascular Disease, and Kidney Related Disorders, Des Plaines, Illinois.
authors.forename: K
authors.initials: K
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Atkin
authors.forename: M L
authors.initials: ML
authors.lastname: Moody
mesh_terms: D000293:Adolescent; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004775:Enuresis / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use*
chemical_list: D000929:Antidepressive Agents, Tricyclic; D010276:Parasympatholytics; D003894:Deamino Arginine Vasopressin